RANI
Rani Therapeutics Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.87
+1.54%Aug 13, 2026, 20:05 UTC
Rani Therapeutics announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing.
Source:Aug 13, 2026, 20:05 UTC
Rani Therapeutics reported financial results for the second quarter ended June 30, 2026.
Source:Aug 13, 2026, 20:05 UTC
Rani Therapeutics entered into a research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill platform.
Source:Aug 13, 2026, 20:05 UTC
Rani Therapeutics completed a $20 million registered direct offering.
Source:Aug 4, 2026, 00:00 UTC
Rani Therapeutics Holdings, Inc. appointed Michelle Gilson as Director and Chair of the Audit Committee, effective August 1, 2026.
Jun 30, 2026, 00:00 UTC
Rani Therapeutics Holdings, Inc. appointed Nicholas M. Maestas as Chief Financial Officer, effective June 29, 2026.
Source: